Travere Therapeutics, Inc.
Company Stats
- Market Cap
- $5.6B
- as of Sep 30, 2026
- Shares Outstanding
- 94.3M
- Free Float
- 92.2%
Income Statement
- Revenue
- $490.7M
- Operating Income
- -$62.8M
- Net Income
- -$25.5M
- EBITDA
- -$2.1M
- Revenue Growth, 3Y
- 64.9%
Balance Sheet
- Cash & Equivalents
- $93.0M
Returns & Capital
- SBC, 3Y Avg
- $42.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $490.7M | — | — |
| FY2024 | $233.2M | — | — |
| FY2023 | $145.2M | -$280.7M | -193.3% |
| FY2022 | $109.5M | -$186.5M | -170.4% |
| FY2021 | $131.8M | -$19.9M | -15.1% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 30, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back